Catherine A. Azar

2.1k total citations
13 papers, 1.1k citations indexed

About

Catherine A. Azar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Catherine A. Azar has authored 13 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Catherine A. Azar's work include HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). Catherine A. Azar is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). Catherine A. Azar collaborates with scholars based in United States, Canada and Ireland. Catherine A. Azar's co-authors include Norman Wolmark, Louis Fehrenbacher, James N. Atkins, Nicholas J. Petrelli, Thomas E. Seay, Séamus O’Reilly, Samia Lopa, Saima Sharif, Michael J. O’Connell and Greg Yothers and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Breast Cancer Research and Treatment.

In The Last Decade

Catherine A. Azar

12 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine A. Azar United States 10 881 362 220 215 163 13 1.1k
Hongnan Mo China 17 1.0k 1.1× 341 0.9× 372 1.7× 427 2.0× 148 0.9× 54 1.5k
E. Magherini France 12 788 0.9× 409 1.1× 154 0.7× 260 1.2× 145 0.9× 24 1.0k
Yifah Yaron United States 11 615 0.7× 149 0.4× 336 1.5× 382 1.8× 146 0.9× 17 1.4k
Cécile Charpy France 13 661 0.8× 194 0.5× 209 0.9× 262 1.2× 139 0.9× 29 1.2k
Yu-Nien Sun United States 10 566 0.6× 196 0.5× 528 2.4× 332 1.5× 152 0.9× 12 1.4k
Casey W. Williamson United States 13 376 0.4× 184 0.5× 301 1.4× 204 0.9× 92 0.6× 30 926
Elisabetta Pietri Italy 15 593 0.7× 364 1.0× 320 1.5× 200 0.9× 78 0.5× 27 909
Anastasia G Eleftheraki Greece 20 612 0.7× 240 0.7× 357 1.6× 316 1.5× 74 0.5× 37 1.2k
J. Lacava Argentina 13 630 0.7× 304 0.8× 226 1.0× 186 0.9× 324 2.0× 31 1.2k
Bernard A. Mason United States 13 926 1.1× 372 1.0× 307 1.4× 662 3.1× 206 1.3× 24 1.4k

Countries citing papers authored by Catherine A. Azar

Since Specialization
Citations

This map shows the geographic impact of Catherine A. Azar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine A. Azar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine A. Azar more than expected).

Fields of papers citing papers by Catherine A. Azar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine A. Azar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine A. Azar. The network helps show where Catherine A. Azar may publish in the future.

Co-authorship network of co-authors of Catherine A. Azar

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine A. Azar. A scholar is included among the top collaborators of Catherine A. Azar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine A. Azar. Catherine A. Azar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Rastogi, Priya, Gong Tang, Saima Hassan, et al.. (2023). Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. Breast Cancer Research and Treatment. 199(2). 243–252. 4 indexed citations
2.
Robidoux, André, Gong Tang, Priya Rastogi, et al.. (2016). Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.. Journal of Clinical Oncology. 34(15_suppl). 501–501. 18 indexed citations
3.
Azar, Catherine A., et al.. (2015). Renal Handling of Glutathione. Contributions to nephrology. 63. 49–52.
4.
Robidoux, André, Gong Tang, Priya Rastogi, et al.. (2013). Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet Oncology. 14(12). 1183–1192. 261 indexed citations
5.
Swain, Sandra M., Gong Tang, Charles E. Geyer, et al.. (2013). Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial. Journal of Clinical Oncology. 31(26). 3197–3204. 89 indexed citations
8.
Robidoux, André, Gong Tang, Priya Rastogi, et al.. (2012). Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.. Journal of Clinical Oncology. 30(15_suppl). LBA506–LBA506. 38 indexed citations
9.
Robidoux, André, Priya Rastogi, Charles E. Geyer, et al.. (2012). Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.. Journal of Clinical Oncology. 30(18_suppl). LBA506–LBA506. 21 indexed citations
10.
Allegra, Carmen J., Greg Yothers, Michael J. O’Connell, et al.. (2010). Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. Journal of Clinical Oncology. 29(1). 11–16. 410 indexed citations
11.
Medeiros, Bruno C., Holbrook E. Kohrt, Daniel A. Arber, et al.. (2009). Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leukemia Research. 34(5). 594–597. 16 indexed citations
12.
Allegra, Carmen J., Greg Yothers, Michael J. O’Connell, et al.. (2009). Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. Journal of Clinical Oncology. 27(20). 3385–3390. 200 indexed citations
13.
Green, Margaret C., Catherine A. Azar, & Thomas H. Maren. (1973). Strain differences in susceptibility to the teratogenic effect of acetazolamide in mice. Teratology. 8(2). 143–145. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026